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Asthma prevalence is increasing with an estimate of 300
million individuals affected worldwide (1). Asthma is a
chronic inﬂammatory disorder of the airways associated with
airway hyperresponsiveness. This causes recurrent episodes of
wheezing, breathlessness, chest tightness and coughing usu-
ally associated with airﬂow obstruction in the lungs (1).
Asthma progression often involves airway remodelling (per-
manent structural changes in airways), which may cause irre-
versible airﬂow obstruction and is associated with poorer
clinical outcome among patients with asthma (2). Airborne
allergens such as house dust mite (HDM) allergens are
strongly associated with asthma. House dust mite sensitiza-
tion commonly initiates the allergic disease manifested as
allergic rhinitis that can progress to allergic asthma. Because
of the allergic march, only few patients with allergic asthma
are still monosensitized as adults (3, 4).
Asthma control is usually achieved by treatment with
inhaled corticosteroids (ICS). Prolonged use of high doses of
ICS may be associated with a risk of systemic side effects,
and although treatment with ICS improves symptoms and
inhibits exacerbations, this treatment is not curative (1).
Therefore, a treatment is needed that can reduce the use of
high doses of ICS, prevent asthma progression to a more
severe state and potentially cure patients.
Treatment with speciﬁc immunotherapy (SIT) induces
immune tolerance to the allergen to which the patient is
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Abstract
Background: Speciﬁc immunotherapy is the only treatment with the potential to pre-
vent progression of the allergic disease and the potential to cure patients. The
immunomodulatory ability of SQ-standardized house dust mite (HDM) subcutane-
ous immunotherapy (SCIT) was investigated in patients with allergic asthma.
Methods: Fifty-four adults with HDM-allergic asthma were randomized 1 : 1 to
receive SQ-standardized HDM SCIT (ALK) or placebo for 3 years. At baseline,
and after 1, 2 and 3 years of treatment, the lowest possible inhaled corticosteroid
dose required to maintain asthma control was determined, followed by determina-
tions of nonspeciﬁc and HDM-allergen-speciﬁc bronchial hyperresponsiveness, late
asthmatic reaction (LAR), immediate and late-phase skin reactions, and immuno-
logical response.
Results: SQ-standardized HDM SCIT provided a statistically signiﬁcantly higher
HDM-allergen tolerance (P < 0.05 vs placebo) in terms of a 1.6-fold increase in
PD20 (HDM-allergen inhalation challenge), a 60-fold increase in skin test histamine
equivalent HDM-allergen concentrations, reduced immediate- and reduced or abol-
ished late-phase skin reactions, as well as fewer patients with LAR. PD20 (methach-
oline inhalation challenge) increased initially and was similar between groups.
House dust mite SCIT induced an initial increase in serum HDM-allergen-speciﬁc
IgE (P = 0.028 vs placebo), which then declined to baseline value. House dust mite
SCIT induced an increase in components blocking IgE binding to allergen [DIgE-
blocking factor: 0.31; 95% CI of (0.26; 0.37)] after 1 year that remained constant
after 2 and 3 years (P < 0.0001 vs placebo).
Conclusion: SQ-standardized HDM SCIT induced a consistent immunomodulatory
effect in adults with HDM-allergic asthma; the humoral immune response was
changed and the HDM-allergen tolerance in lung and skin increased.
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to alter the natural course of the disease (5, 6). Speciﬁc
immunotherapy has been shown to be effective in patients
with allergic asthma in terms of reducing asthma symptom
score and medication requirements, and improve bronchial
hyperresponsiveness (BHR) (7). Speciﬁc immunotherapy has
also been shown to prevent progression of allergic rhinitis
into asthma (8, 9) and to provide sustained effect after treat-
ment cessation in allergic patients (8, 10, 11). As concluded
in the recent Cochrane collaboration report, trials are
required to elicit the effect of SIT compared with other thera-
pies, as well as the effect of SIT with concurrent steroid ther-
apy in patients with allergic asthma (7).
Previously, we reported that 3 years of SQ-standardized
HDM subcutaneous immunotherapy (SCIT) was generally
well tolerated and partly replaced the need for ICS treatment
to control asthma in adults with HDM-allergic asthma; HDM
SCIT had a steroid-sparing effect (12). From the same trial,
we now present the difference in treatment efﬁcacy between
patients treated with SQ-standardized HDM SCIT plus ICS
and patients treated with placebo plus ICS in terms of nonspe-
ciﬁc and HDM-allergen-speciﬁc BHR, late asthmatic reaction
(LAR), lung function, HDM-allergen-speciﬁc immediate- and
late-phase skin reactions and immunological response (HDM-
allergen-speciﬁc IgE and IgE-blocking factor).
Materials and methods
Patients
A total of 54 out of 112 screened patients aged 18–60 were
included: 32 men and 22 women. Details of inclusion and
exclusion criteria are described elsewhere (12). In short, eligi-
ble patients had:
l HDM allergy and perennial asthma (medical history con-
sistent with HDM allergy).
l Regular asthma symptoms requiring long-term treatment
with inhaled ICS of at least daily doses of 500–2000 lg ﬂuti-
casone propionate to control asthma.
l A forced expiratory volume in 1 s (FEV1) >70% of pre-
dicted value.
Trial design and treatment
Written informed consent was obtained before entering the
trial, and the trial was performed in accordance with current
GCP standards and the Declaration of Helsinki (13).
Trial design and treatment regimen are described in
detail elsewhere (12). In short, it was a 3-year, double-blind,
placebo-controlled trial. Patients were randomized 1 : 1 to
receive SCIT with Alutard
  SQ Dermatophagoides pterony-
ssinus (D. pteronyssinus; ALK, Hørsholm, Denmark) or
placebo.
Treatment included an ‘8-week’ up-dosing (up to 100 000
SQ-U) and a ‘3-year’ maintenance with injection intervals of
6 ± 2 weeks. The placebo group received histamine injec-
tions according to the same dose increase and maintenance
schedule (0.00001, 0.0001, 0.001 and 0.01 mg histamine/ml).
Patients were also treated with ICS to control their
asthma, giving two treatment groups: HDM SCIT plus ICS
and placebo SCIT plus ICS. The lowest possible dose of ICS
that maintained asthma control in each patient was deter-
mined by a stepwise reduction protocol at baseline and after
1, 2 and 3 years of treatment (September–December).
Asthma control was deﬁned as ‘the ICS dose one step higher
than when patients had uncontrolled symptomatic asthma’.
Rescue medication (Salbutamol) was allowed as needed. Tol-
erability was evaluated by adverse event reporting.
The efﬁcacy measures described in the following paragraph
were performed at baseline and after 1, 2 and 3 years of
treatment, just after the ICS dose adjustment.
Bronchial challenge tests
Determination of nonspeciﬁc BHR. The methacholine bronchial
challenge test was carried out with the dosimeter method (14)
using a Spira Elektro II
TM nebuliser (Respiratory Care Centre,
Hameenlinna, Finland). Patients inhaled a ﬁxed amount of
solution (nebulization time 0.5 s, start of nebulization at
50 ml, working pressure 2 atm), inspiratory ﬂow of 50 l/s;
inspiratory volume of 500–800 ml. FEV1 was measured before
provocation and 90 s after each inhalation. Methacholine was
administered in doubling doses from 18 to 11 520 lg. Bron-
chial challenge was terminated when FEV1 decreased at least
20% compared with the patient’s FEV1 measured after a saline
inhalation. The decrease in FEV1 was plotted against the
methacholine dose (log scale) and the cumulative dose causing
a 20% decrease in FEV1 (PD20) was determined. The severity
of nonspeciﬁc BHR was deﬁned as follows: no BHR,
PD20>2000 lg; mild BHR, 1000 lg<PD 20 £ 2000 lg;
moderate BHR, 250 lg £ PD20 £ 1000 lg; severe BHR,
PD20<250 lg.
Determination of HDM-allergen-speciﬁc BHR. The HDM-
allergen bronchial challenge test was also carried out with the
dosimeter method (14). A dry extract of D. pteronyssinus
(Aquagen
  SQ, 1 000 000 SQ-U/vial) was diluted to concen-
trations of 1000; 10 000; and 100 000 SQ-U/ml (ALK). Three
breathing steps were used for each allergen concentration
(two, four and eight breaths) and the cumulated allergen dose
for each breathing step was calculated. Baseline FEV1 was
determined 15 min after two initial inhalations with diluent.
The maximum allergen dose delivered was 2 breaths of 1000
SQ-U + 2 breaths of 10 000 SQ-U + (2 + 4 + 8 breaths)
of 100 000 SQ-U = 1 422 000 SQ-U. FEV1 was measured
before and 15 min after each inhalation. Bronchial challenge
was terminated when FEV1 decreased at least 20% compared
with the patient’s baseline FEV1. The decrease in FEV1 was
plotted against the HDM-allergen dose (log scale), and the
provocative dose causing a 20% decrease in FEV1 (PD20)
determined. PD20 was considered to be 2 844 000 SQ-U if a
patient failed to reach a 20% decline in FEV1.
FEV1 was measured according to guideline on a daily cali-
brated dry wedge spirometer (Vitalograph
 , Buckingham,
UK) and the percentage of predicted value calculated (15).
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Patients were provided with an electronic spirometer (Asthma
monitor-1; Erish Jaeger GmbH, Hoechberg, Germany) to
record their peak expiratory ﬂow (PEF) at home every hour
for 24 h after allergen challenge (except during sleep). Late
asthmatic reaction was deﬁned as a surplus administration of
beta-2 agonist because of asthma symptoms or a fall in PEF
of at least 15% from the maximum value after recovery from
the early-phase reaction. Morning and evening PEF was
recorded over the entire trial.
Skin prick test titration
Dilutions of 1, 10 and 100 Histamine Equivalent in Prick
(HEP) of D. pteronyssinus allergen extract (ALK) were used
for skin prick test titration (SPTT) on the volar side of the
forearm. Positive and negative controls were diluents with or
without histamine dihydrochloride (10 mg/ml). Skin reactions
(weal area) were measured after 10 min (controls) and after
15 min (HDM-allergen extracts) (New Genius Scanner 4500;
Software Genius Inc, Iselin, NJ, USA) (16).
Intradermal allergen challenge
Intradermally, 0.02 ml (20 SQ-U) of Aquagen
  SQ D. pter-
onyssinus (1000 SQ-U/ml; ALK) was injected in the skin of
the forearm and a negative control injected in the opposite
arm. Immediate-phase skin reactions were determined after
15 min and late-phase skin reactions were determined after
24 h (New Genius Scanner 4500; Genius) (16). The size of
the weal area was classiﬁed as: (i) no response: <1 cm
2; (ii)
moderate response: 1–20 cm
2; (iii) severe response: >20 cm
2.
Immunological response
Serum speciﬁc IgE against D. pteronyssinus was determined
using Magic Lite
  SQ (ALK).
Serum speciﬁc IgE-blocking factor against D. pteronyssinus
was determined using the ADVIA Centaur immunoassay sys-
tem (Siemens Medical Solutions, Diagnostics, Tarrytown, NY,
USA): IgE-blocking factor was calculated as: 1 – (competed
speciﬁc IgE/speciﬁc IgE); speciﬁc IgE is the ordinary determi-
nation: the total amount of allergen-speciﬁc IgE antibodies that
bind to allergen without competing antibodies/components in
the solution; competed speciﬁc IgE is the total amount of aller-
gen-speciﬁc IgE antibodies that bind to allergen in the potential
presence of competing components; IgE-blocking factor is
the inhibiting capacity of competing components to speciﬁc
IgE-allergen binding and varies theoretically from 0 (no pres-
ence of IgE-blocking components) to 1 (all allergen-speciﬁc
IgE antibodies are blocked from binding to allergen) (17).
Statistical analysis
Statistical analyses were performed on the full analysis set
(FAS) using the available data without imputation of missing
values. Endpoints were tested on a 5% signiﬁcance level, and
all tests and conﬁdence intervals (CI) were two-sided. The null
hypothesis was no difference between the two groups. There
was no adjustment for multiplicity. Doses of methacholine (lg)
and HDM-allergen (SQ-U), as well as the concentration of spe-
ciﬁc IgE (kU/L) were log10-transformed for normality. These
data and serum IgE-blocking factor were analysed in anova
with change from baseline as response variable, treatment as
ﬁxed effect and baseline as covariate. The proportions of
patients experiencing a LAR were tested using Fischer’s exact
test with exact 95% conﬁdence intervals. In the SPTT, the
HDM-allergen dose (in HEP) and skin reactions (weal area in
cm
2) were log10-transformed for normality. A statistical paral-
lel line regression model was applied to obtain the histamine
equivalent HDM-allergen concentration. The immediate- and
late-phase skin reactions were analysed with nonparametric
Wilcoxon Rank Sum Test. sas
  statistical software, Version
8.2 (SAS Institute, Cary, NC, USA) was used.
Results
Patients and tolerability
We included 54 patients with HDM-allergic asthma; 26
patients received HDM SCIT plus ICS (SCIT group) and 28
patients received placebo SCIT plus ICS (placebo group).
These two groups were comparable with regard to baseline
characteristics (Table 1). Treatment was generally well toler-
ated; no life-threatening or other serious adverse events
related to treatment were reported. Three patients withdrew
because of adverse events (two intercurrent illnesses and one
worsening of condition) and three patients withdrew because
of pregnancies. The trial was completed by 20 patients in the
SCIT group and 22 patients in the placebo group. Further
details on patient characteristics, safety results and the trial
ﬂow according to the CONSORT statement (18) are
described elsewhere (12).
Bronchial hyperresponsiveness to inhaled methacholine and
lung function
At baseline, 42% in the SCIT and 64% in the placebo group
experienced moderate to severe BHR to inhaled methacholine
(PD20 £ 1000 lg methacholine) despite receiving high doses
of ICS (500–2000 lg) to control their asthma. PD20 increased
from baseline to 1 year in both the SCIT and the placebo
groups and stayed constant after 2 and 3 years. The change
from baseline in log10(PD20) was similar between treatment
groups after 1, 2 and 3 years (Fig. 1A).
Morning and evening PEF was unchanged in both treat-
ment groups after 1, 2 and 3 years (data not shown).
Bronchial hyperresponsiveness to inhaled HDM-allergen
At baseline, 44 patients (81%) had at least a 20% decline in
FEV1 after HDM-allergen challenge despite receiving high
doses of ICS (500–2000 lg) to control their asthma.
In the SCIT group, PD20 increased from baseline to 1 year
[Dlog10(PD20): 0.49; 95% CI of (0.32; 0.66)], stayed constant
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corresponded to an initial increase by a factor 1.6 from a
median PD20 of 552 SQ-U to 857 SQ-U. PD20 slightly
increased in the placebo group from baseline to 1 year
[Dlog10(PD20): 0.18; 95% CI of (0.020; 0.33)] and then
declined to baseline value (Fig. 1B).
The differences in change from baseline between groups
were statistically signiﬁcant, in favour of SCIT, for all 3 years
(P = 0.0089; P = 0.0001; P = 0.0319) (Fig. 1B).
Late asthmatic reaction
At baseline, 28 patients (52%) experienced a LAR; 13 of
these patients received SCIT and 15 received placebo. After
1 year of treatment, seven patients in the SCIT group [30%;
95% CI of (13; 53)] and 20 patients in the placebo group
[77%; 95% CI of (56; 91)] experienced a LAR (Fig. 2;
P = 0.0016 vs placebo). The percentage of patients with a
LAR in the SCIT group was also lower than in the placebo
group after 2 and 3 years (Fig. 3).
Skin prick test titration
At baseline, the estimated HDM-allergen concentration that
caused histamine equivalent skin reactions was similar
between groups (Fig. 3). This concentration increased from 6
to 377 HEP in the SCIT group and from 6 to 48 HEP in the
placebo group after 3 years of treatment (Fig. 3); the differ-
ence between groups was statistically signiﬁcant for all
3 years (P < 0.0001).
Intradermal allergen challenge
At baseline, the immediate-phase skin reactions were similar
between the two groups: a median weal area of 24 cm
2 in
SCIT vs 21 cm
2 in placebo. After 1 year of SCIT, the reac-
tion was reduced to a median weal area of 13 cm
2, after
2 years to 10 cm
2, which remained constant after 3 years of
SCIT (11 cm
2). This reduction was statistically signiﬁcantly
higher than in the placebo group after all 3 years of treat-
ment (P < 0.04) (Fig. 4A).
At baseline, the late-phase skin reactions were similar
between the two treatment groups: a median weal area of
Table 1 Baseline characteristics (FAS)
HDM SCIT
N =2 6
Placebo
N =2 8
Sex
Female 15 17
Males 11 11
Age (years, mean ± SD) 29.8 ± 10.7 28.5 ± 7.1
Asthma severity
Moderate persistent
(step 2.2 and 2.3)*
20 22
Severe persistent (step 2.4) 66
Asthma duration
(years, mean ± SD)
14.8 ± 9.7 14.1 ± 6.9
Morning PEF (mean ± SD) 511 ± 111 499 ± 80.1
ICS dose (lg/day)
500 8 13
750 1 6
1000 11 3
1500 4 5
2000 2 1
FAS, full analysis set; HDM, house dust mite; ICS, inhaled cortico-
steroid; PEF, peak expiratory ﬂow; SCIT, subcutaneous immuno-
therapy. All patients were caucasians.
*According to GINA, asthma severity is moderate when the ICS
dose required for asthma control is >500 lg and £1000 lg ﬂutica-
sone propionate/day.
According to GINA, asthma severity is severe when the ICS dose
required for asthma control is >1000 lg ﬂuticasone propionate/day.
Baseline PEF was measured during 4 weeks in January. FEV1 was
<70% of predicted in all patients.
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Figure 1 (A) The nonspeciﬁc bronchial hyperresponsiveness (BHR)
in terms of change from baseline in log10(PD20); estimate and 95%
conﬁdence intervals with P-values for the difference between treat-
ment groups. PD20 is the methacholine dose (lg) causing a 20%
decline in FEV1. Test: ANOVA with change from baseline as response
variable, treatment as ﬁxed effect and baseline as covariate. (B)
The house dust mite (HDM)-allergen-speciﬁc BHR in terms of
change from baseline in log10(PD20); estimate and 95% conﬁdence
intervals with P-values for the difference between treatment
groups. PD20 is the HDM-allergen dose (SQ-U) causing a 20%
decline in FEV1. Test: ANOVA with change from baseline as response
variable, treatment as ﬁxed effect and baseline as covariate.
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2 in SCIT vs 26 cm
2 in placebo. In the SCIT group, the
late-phase skin reaction was reduced to 1 cm
2 after 1 year and
0c m
2 (no reaction) after 2 and 3 years. As a contrast, this reac-
tion was unchanged in the placebo group and statistically
signiﬁcantly different from that in the SCIT group after all
3 years (P < 0.002) (Fig. 4B).
In the SCIT group, the percentage of patients without a
late-phase skin reaction increased from 8% at baseline to
65% after 3 years; none of the patients had a severe reaction
(weal area >20 cm
2) after 2 and 3 years (Fig. 4C). In con-
trast, the percentage of patients with a late-phase skin reac-
tion in the placebo group was constant over 3 years and 55%
experienced a severe reaction after 3 years (Fig. 4C).
Immunological response
In the SCIT group, the change from baseline to 1 year in
serum speciﬁc IgE (D. pteronyssinus)[ Dlog10(IgE): 0.048; 95%
CI of ()0.017; 0.11)] was statistically signiﬁcantly different
from that in the placebo group [P = 0.028; Dlog10(IgE):
)0.051; 95% CI of ()0.11; 0.0080)]. In the SCIT group, speci-
ﬁc IgE declined to baseline value after 2 and 3 years, and the
difference between treatment groups at year 2 and 3 was
statistically insigniﬁcant.
In the SCIT group, the increase from baseline to 1 year in
serum speciﬁc IgE-blocking factor (D. pteronyssinus)[ DIgE-
blocking factor: 0.31; (0.26; 0.37)] remained constant after 2
and 3 years (Fig. 5). There was no change from baseline in
the placebo group and a statistically signiﬁcant difference
between treatment groups, in favour of SCIT, was found for
all 3 years (P < 0.0001) (Fig. 5).
Discussion
Treatment with SIT induces immune tolerance to the allergen
to which the patient is allergic and is the only treatment with
the potential to alter the natural course of the disease (5, 6).
Patients with HDM-allergic asthma were treated with HDM
SCIT plus ICS or placebo plus ICS for 3 years. Each year,
ICS was adjusted to the minimal dose that maintained the
patient’s asthma in control and the efﬁcacy and tolerability
of SCIT was evaluated accordingly. We previously reported
that SCIT reduced the ICS dose that maintained asthma in
control and was well tolerated in HDM-allergic patients with
moderate asthma (12).
We found that nonspeciﬁc BHR was reduced similarly in
both groups after 1 year. Methacholine acts as direct stimuli
of BHR by binding to speciﬁc receptors on the bronchial
smooth muscle to cause constriction (19). Regular treatment
with ICS is known to progressively reduce the patient’s sensi-
tivity to this stimuli (20), and we found that SCIT fully
replaced this effect over 3 years. However, nonspeciﬁc BHR
was not fully reversed in any of the groups; persistent BHR
has been found to correlate signiﬁcantly with airway remod-
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Figure 3 In the skin prick test titration, the house dust mite-
allergen dose (in HEP) and skin reactions (weal area in cm
2) were
ln-transformed. A statistical parallel line regression model was
applied. The histamine equivalent Dermatophagoides pteronyssinus
allergen concentrations at baseline and after 1, 2, and 3 years of
active treatment (A) and placebo treatment (B) are plotted. HEP,
Histamine Equivalent in Prick.
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Lung function was also unchanged in both groups after
3 years of treatment. Overall, supporting previous ﬁndings
that HDM SCIT partly replaced ICS in providing asthma
control (12).
Both immediate- and late-phase reactions to HDM aller-
gens were markedly more reduced in SCIT plus ICS treated
patients than in patients treated only with ICS. House dust
mite-allergens act indirectly by inducing the allergic reaction
causing BHR and skin reactions; an immediate IgE-mediated
mast-cell-driven response within 15–30 min, and for some, a
late-phase allergic inﬂammation 6–12 h after allergen expo-
sure (19, 23). Measuring allergen-speciﬁc BHR and skin reac-
tions to HDM-allergen is, therefore, a direct measure of
allergen tolerance in lungs and skin that can indicate if treat-
ment improves the underlying allergic disease manifested as
asthma. In this trial, patients treated with SCIT tolerated a
higher inhaled HDM-allergen dose when challenged (PD20
increased), fewer patients experienced a LAR to inhaled
HDM-allergen challenge, the histamine equivalent concentra-
tion was higher at SPTT and the immediate-phase skin
reaction was reduced. The late-phase skin reactions were
strikingly diminished or abolished in the SCIT group and
none of these patients experienced a severe late-phase skin
reaction after only 2 years of treatment. Conclusively, HDM
SCIT provided improved tolerability to HDM allergens in
skin and lungs.
After SCIT, the suppression of early reactions in skin has
been found associated with reduction in mast-cell numbers
(23–25), and suppression of late-phase skin reaction has
been found associated with reduction in the number of inﬁl-
trating T cells, eosinophils, basophils and neutrophils and
inﬂammatory mediators (23, 26). Thus, the increased aller-
gen tolerability observed in this trial is probably because of
a reduced allergic inﬂammation as a consequence to SCIT
improving the underlying allergic disease.
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Figure 4 (A) Median areas (in cm
2) of the immediate-phase skin
reactions for each treatment group at baseline and after 1, 2 and
3 years of treatment with P-values for the difference between
treatment groups (Wilcoxon Rank Sum Test). (B) Median areas
(in cm
2) of the late-phase skin reactions for each treatment group
at baseline and after 1, 2 and 3 years of treatment with P-values
for the difference between treatment groups (Wilcoxon Rank Sum
Test). (C) The percentage (%) of patients without a late-phase skin
reaction (weal area <1 cm
2), the percentage of patients that experi-
enced intermediate reactions (weal area 1–20 cm
2) and the per-
centage of patients that experienced a severe reaction (weal area
>20 cm
2) are illustrated at baseline, and after 1, 2 and 3 years of
treatment for both house dust mite (HDM) subcutaneous immuno-
therapy (SCIT) and placebo treatment groups.
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allergic reaction (27) and is increased in serum of patients
with allergy (28). In this trial, SCIT also provided a change
in the humoral immune response, which was absent in
patients treated only with ICS; an initial increase in serum
HDM-allergen-speciﬁc IgE antibodies followed by a decline
and a marked increase in the effect of components blocking
HDM-allergen-speciﬁc IgE function. The precise mechanism
by which SIT acts remains unclear; however, consistent with
the ﬁndings in this trial, an effect on IL-10 and TGF-b
secreting regulatory T cells (Treg) associated with switching
of allergen-speciﬁc B-cells towards IgG4 production and
suppression of allergen-speciﬁc IgE production is the most
probable mechanism (23, 25, 29). This was also observed by
others (30, 31), and probably reduce the immediate IgE-medi-
ated mast-cell-driven allergic response and thereby also
reduce the release of inﬂammatory mediators that induce the
late-phase response, in this trial observed as reduced immedi-
ate- and late-phase reactions in lung and skin.
Treg may also directly inhibit the activation of allergen-
speciﬁc Th2 cells, thereby reducing the production of Th2-
cytokines and their multiple effects on cells involved in the
allergic response (23). Chen et al. demonstrated that 1 year
of SQ-standardized HDM SCIT signiﬁcantly decreased the
serum level of the Th2-cytokine IL-13 (involved in the patho-
genesis of airway remodelling) more than did ICS in children
with asthma (32). At the same time, the serum level of IL-4
(a Th2-cytokine) decreased and the serum level of IFN-c
(a Th1-cytokine) increased (32). This shift from an allergic
‘Th2 cell predominance’ to a more normal ‘type 1 Treg cell
predominance’ immune response to allergen that also
involves a shift in the balance of Th2 and Th1 cytokine
expression (6, 23, 25, 29) is also observed in allergic rhinitis
after SIT, consistent with the idea of a one-airway-one-
disease theory (33–35). Therefore, the prevention of disease
progression (8, 9) and sustained effect (8, 10, 11) observed in
patients with allergic rhinitis after SIT may also be expected
treatment outcomes in patients with allergic asthma.
Because of the added beneﬁt over ICS, we recommend that
SIT is considered as ﬁrst-hand medication when treating
patients with HDM-allergic asthma. Because of current
knowledge and current guidelines on asthma treatment
(GINA) (1), initial treatment is suggested to consist of SIT
combined with controller medication in terms of inhaled ICS
and reliever medication as needed. This trial indicates that
over time, SIT will improve the underlying allergic disease in
the majority of patients with asthma; the ICS dose can be
down-titrated accordingly. For some patients with asthma,
SCIT may ultimately become sufﬁcient to control their
asthma in combination with reliever medication.
In conclusion, SQ-standardized HDM SCIT induced a con-
sistent immunomodulatory effect in adults with HDM-allergic
asthma in terms of a change in the humoral immune response
and as increased HDM-allergen tolerance in the lungs and
skin of these patients. This strongly indicates that HDM
SCIT treats the underlying allergic disease; sustained effect
and prevention of disease progression may be expected treat-
ment outcomes for the patient with HDM-allergic asthma.
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